CF
BNTC icon

Cantor Fitzgerald’s Benitec Biopharma BNTC Stock Holding History

Cantor Fitzgerald’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497K Buy
+46,659
New +$540K 0.01% 219
2023
Q2 		– Sell
-1,474
Closed -$5.26K – 581
2023
Q1 		$5.26K Hold
1,474
– – ﹤0.01% 646
2022
Q4 		$4K Sell
1,474
-6,397
-81% -$21.7K ﹤0.01% 676
2022
Q3 		$50K Buy
+7,871
New +$100K ﹤0.01% 654

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cantor Fitzgerald's BNTC Position: Q1 2026 in Review

Cantor Fitzgerald opened a new position in Benitec Biopharma (BNTC) in Q1 2026: 46,659 shares worth $497K. The stake represents 0.01% of the portfolio and ranks #219 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in BNTC as recently as Q1 2023.

Cantor Fitzgerald first reported a position in BNTC in Q3 2022 and has held it in 4 quarters since. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Cantor Fitzgerald held 46,659 shares of Benitec Biopharma worth $497K as of Q1 2026.
  • Benitec Biopharma was a new Cantor Fitzgerald position in Q1 2026.
  • Benitec Biopharma made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #219 holding.
  • Cantor Fitzgerald first reported a position in Benitec Biopharma in Q3 2022 and has held it in 4 quarters since.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.